ArticleVeterinary research2025
Proanthocyanidins carbon dots inhibit PRRSV infection by activating Nrf2/ARE to regulate oxidative stress and NLRP3 inflammasome-mediated pyroptosis.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Carbon-derived nanomaterials, especially carbon dots (CDs), are gaining attention for their distinct physicochemical characteristics and broad-spectrum antiviral capabilities. However, their efficacy against economically critical pathogens like porcine reproductive and respiratory syndrome virus (PRRSV), a major threat to swine health-and the molecular pathways involved remain underexplored. Here, we developed innovative proanthocyanidin-based carbon dots (PAC-CDs) to enhance their antiviral efficacy against PRRSV by targeting oxidative stress pathways and suppressing NLRP3 inflammasome-mediated pyroptosis via activation of the Nrf2/ARE antioxidant axis. PAC-CD were synthesized as uniformly dispersed spherical nanostructures averaging 5.49 nm in diameter, exhibiting exceptional aqueous solubility and biocompatibility. These nanoparticles significantly suppressed PRRSV replication in both Marc-145 and porcine alveolar macrophage (PAM) cells, while mitigating infection-induced cytopathic damage. Mechanistically, PAC-CDs exert their antiviral effects not through direct viral neutralization but by hindering viral entry and replication via Nrf2 pathway activation, which upregulates antioxidant defenses and reduces oxidative damage. Consistently, PAC-CDs impaired PRRSV-induced NLRP3 inflammasome-triggered pyroptotic cell death and downstream pro-inflammatory cytokine release. These findings advance the development of targeted antiviral therapies and highlight the translational potential of PAC-CDs against PRRSV outbreaks, offering a dual-action strategy to alleviate oxidative injury and inflammatory cascades in infected hosts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.